Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TCF4 | P15884 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639745 | 1.00 | MEN1 (0.55) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL25284012 | 0.89 | HTT (0.53) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL9210604 | 0.88 | HTT (0.59) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL63797 | 0.85 | ALDH1A1 (0.55) | MEN1KMT2AMAPTHSD17B10ALDH1A1 | |
| SCHEMBL480863 | 0.85 | MEN1 (0.58) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL29639744 | 0.85 | MEN1 (0.58) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL30132562 | 0.84 | SHBG (0.55) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL20554833 | 0.84 | SHBG (0.55) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL2943808 | 0.80 | HPGD (0.50) | MEN1KMT2AMAPTHSD17B10ALDH1A1 | |
| SCHEMBL26384131 | 0.79 | SHBG (0.58) | MEN1KMT2AMAPTSHBGHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2021085321-A1 | RESIN COMPOSITION, RESIN SHEET, CURED FILM, METHOD FOR MANUFACTURING CURED FILM, SEMICONDUCTOR DEVICE, ORGANIC EL DISPLAY DEVICE, AND DISPLAY DEVICE | 東レ株式会社 | 2021-05-06 | — | — | WO | disclosed |
| CN-109293493-A | With the inhibition active novel benzhydryl class compound of mycobacterium tuberculosis | 清华大学 | 2019-02-01 | — | — | CN | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9221811-B2 | Chromone derivative having osteogenesis promoting effect | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| EP-2808322-A1 | CHROMONE DERIVATIVE HAVING OSTEOGENESIS PROMOTING EFFECT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-20140349991-A1 | CHROMONE DERIVATIVE HAVING OSTEOGENESIS PROMOTING EFFECT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-7629400-B2 | Image making medium | HYMAN SYDNEY | 2009-12-08 | — | — | US | disclosed |
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349991-A1 | CHROMONE DERIVATIVE HAVING OSTEOGENESIS PROMOTING EFFECT | COL1A1, BMP2, COL2A1 | MEN1 4535/4885KMT2A 4154/4885MAPT 3526/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MEN1 3296/4885KMT2A 944/4885MAPT 1240/4885 |
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | MEN1 4561/4885KMT2A 2408/4885MAPT 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.